Press Releases
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
Agomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors
Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis
Loading...
End of content
No more pages to load
Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis
Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
Loading...
End of content
No more pages to load
Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022
Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
Loading...
End of content
No more pages to load
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics to Acquire Origo Biopharma
AgomAb Therapeutics Expands Senior Team with General Counsel and Head of Clinical Operations
AgomAb Announces Two Oral Presentations at the EASL Liver Congress 2021
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
Loading...
End of content
No more pages to load
AgomAb Therapeutics Closes Series A Extension Round with Additional Funding from Andera Partners
AgomAb Therapeutics Completes €21m Series A Financing
Loading...
End of content
No more pages to load
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
Agomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors
Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis
Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis
Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022
Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics to Acquire Origo Biopharma
AgomAb Therapeutics Expands Senior Team with General Counsel and Head of Clinical Operations
AgomAb Announces Two Oral Presentations at the EASL Liver Congress 2021
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
AgomAb Therapeutics Closes Series A Extension Round with Additional Funding from Andera Partners
AgomAb Therapeutics Completes €21m Series A Financing
Loading...
End of content
No more pages to load
Looking to connect with us?
8-10 October
Laguna, CA, USA
Jefferies Conference
14-16 November
London, United Kingdom
BCF Career Event
23 November
Ghent, Belgium
JP Morgan Conference
8-11 January
San Francisco, CA, USA